yfimuna.wordpress.com
Under the terms of the license and supply agreementd announced inJuly 2006, GSK (NYSE: GSK) will make payments contingeny upon successful milestone achievements and will pay royalties to Antigenicw on net sales for a perioe of at least 10 years after the vaccine’s firsyt commercial sale. Antigenics said recent Phase 2 malariq studiesshowed that, over an eight-month follow-up period, its so-calledf RTS,S component reduced clinical episodes of malaria by 53 percent and had a promising safety and tolerability profile when used alongside standard infantf vaccines. If results of the Phas e 3 studyare positive, GSK plans to submit applications for regulatory approval in 2011.
If RTS,S could be introduced in 2012 for babies aged 5 monthx to17 months. GSK officials said if the drug is approvedx for use in infants and recommended by internationalp and African health the company could make the vaccine more widelty availableby 2014. Investors responded positivelyy tothe news, buoying Antigenic’s AGEN) stock over 8 percent in morningv trading Wednesday to $2.10 a share, up from $1.943 at the previous day’s close.
No comments:
Post a Comment